No Data
Harbin Medisan Pharmaceutical (002900.SZ): The sodium calixarene injection has passed the consistency evaluation of generic drug quality and efficacy.
Gelonghui, April 3rd | Harbin Medisan Pharmaceutical (002900.SZ) announced that the company recently received the approval notification for the supplemental application for pharmaceuticals issued by the National Medical Products Administration. The pharmaceutical Carboxymethylsodium Injection has passed the consistency evaluation for generic drugs (hereinafter referred to as "consistency evaluation"). Carboxymethylsodium Injection is used for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology. It is particularly effective for the urinary system and can also be used for the prevention and treatment of surgical bleeding.
Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Most Bullish Insider Is CEO Jian Fei Qin, and Their Holdings Value Went up by 14% Last Week
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Harbin Medisan Pharmaceutical (002900.SZ): All initial fundraising projects have been completed, and the surplus funds will permanently supplement working capital.
On February 18, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) announced that all funds raised from the initial public offering of stocks have reached the predetermined usable status, and the company will conclude all funded projects. In order to maximize the efficiency of fund use, the company intends to permanently supplement working capital with the remaining raised funds of 81.8757 million yuan (estimated amount, including financial investment income and bank deposit interest, with the actual amount based on the special account balance on the date of fund transfer) until January 31, 2025. After the transfer is completed, the company will terminate the special account for the raised funds.
Harbin Medisan Pharmaceutical (002900.SZ): Some formulation products have now achieved overseas sales.
On February 18, Gelonghui reported that Harbin Medisan Pharmaceutical (002900.SZ) stated on the investor interaction platform that some of its formulation products have already achieved overseas sales, primarily in South America, while also developing other markets.